Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals

Published:August 06, 2021DOI:https://doi.org/10.1016/j.jinf.2021.08.005
      In this Journal, the emergence of novel variants with potential to escape vaccine-induced immunity has received commentary.
      • Tang J.W.
      • Tambyah P.A.
      • Hui D.S.
      Emergence of a new SARS-CoV-2 variant in the UK.
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tang J.W.
        • Tambyah P.A.
        • Hui D.S.
        Emergence of a new SARS-CoV-2 variant in the UK.
        J Infect. 2021; 82: e27-e28
        • Pereira F.
        • Tosta S.
        • Lima M.M.
        • Reboredo de Oliveira da Silva L.
        • Nardy V.B.
        • Gómez M.K.A.
        • et al.
        Genomic surveillance activities unveil the introduction of the SARS-CoV-2 B1.525 variant of interest in Brazil: case report.
        J Med Virol. 2021; (Epub ahead of print)
        • Janik E.
        • Niemcewicz M.
        • Podogrocki M.
        • Majsterek I.
        • Bijak M.
        The Emerging Concern and Interest SARS CoV-2 Variants.
        Pathogens. 2021; 10: 633
        • Vicenti I.
        • Gatti F.
        • Scaggiante R.
        • Boccuto A.
        • Zago D.
        • Basso M.
        • et al.
        Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection.
        Int J Infect Dis. 2021; 108: 176-178
        • Liu J.
        • Liu Y.
        • Xia H.
        • Zou J.
        • Weaver S.C.
        • Swanson K.A.
        • et al.
        BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
        Nature. 2021;
        • Zani A.
        • Caccuri F.
        • Messali S.
        • Bonfanti C.
        • Caruso A.
        Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
        Emerg Microbes Infect. 2021; 7: 1-6
        • Betton M.
        • Livrozet M.
        • Planas D.
        • Fayol A.
        • Monel B.
        • Védie B.
        • et al.
        Sera neutralizing activities against SARS-CoV-2 and multiple variants six month after hospitalization for COVID-19.
        Clin Infect Dis. 2021; (; ciab308. Epub ahead of print. PMID: 33851216; PMCID: PMC8083257)https://doi.org/10.1093/cid/ciab308
        • Planas D.
        • Bruel T.
        • Grzelak L.
        • Guivel-Benhassine F.
        • Staropoli I.
        • Porrot F.
        • Planchais C.
        • et al.
        Sensitivity of infectious SARS-CoV-2 B1.1.7 and B.1.351 variants to neutralizing antibodies.
        Nat Med. 2021; 27: 917-924
        • Wang P.
        • Casner R.G.
        • Nair M.S.
        • Wang M.
        • Yu J.
        • Cerutti G.
        • Liu L.
        • et al.
        Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization.
        Cell Host Microbe. 2021; 29 (e4): 747-751
        • Wang P.
        • Nair M.S.
        • Liu L.
        • Iketani S.
        • Luo Y.
        • Guo Y.
        • et al.
        Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
        Nature. 2021; 593: 130-135